IDH1 and central nervous system cancer: Recently, an inhibitor of mutant forms of IDH1 and IDH2 has been synthesized (vorasidenib) and has been approved by the Food and Drug Administration for grade 2 IDH-mutant glioma under the name VORANIGO (21).